Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma
Molecular Subtyping Based on Specific HLA-I Genotypes for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma: A Retrospective Observational Cohort Study
1 other identifier
observational
226
1 country
1
Brief Summary
Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 14, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 3, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 13, 2021
CompletedFirst Submitted
Initial submission to the registry
July 29, 2022
CompletedFirst Posted
Study publicly available on registry
August 2, 2022
CompletedAugust 2, 2022
July 1, 2022
2.4 years
July 29, 2022
July 31, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disease-free survival (DFS)
Comparison of DFS between patients with specific HLA-I genotypes or not
2 years
Interventions
HLA-I genotyping based on next-generation sequencing for prognosis evaluation
Eligibility Criteria
Radically resected patients with pancreatic adenocarcinoma
You may qualify if:
- Radically resected pancreatic adenocarcinoma (stage I-III)
- Resected tumor tissues and matched blood cells available
- Signed informed consent
You may not qualify if:
- Pancreatic cancer except pancreatic adenocarcinoma
- Non-radical resection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- BAIYONG SHENlead
- GeneCast Biotechnology Co., Ltd.collaborator
Study Sites (1)
Ruijin Hospital
Shanghai, Shanghai Municipality, 200025, China
Related Publications (1)
Wen C, Zhang L, Yang Y, Jin Y, Ren D, Zhang Z, Zou S, Li F, Sun H, Jin J, Lu X, Xie J, Cheng D, Xu Z, Chen H, Mao B, Zhang J, Wang J, Deng X, Peng C, Li H, Jiang C, Lin L, Zhang H, Chen H, Shen B, Zhan Q. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1941-1952. doi: 10.1097/JS9.0000000000000264.
PMID: 37026827DERIVED
Biospecimen
Matched blood cells and tumor tissues
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 29, 2022
First Posted
August 2, 2022
Study Start
March 14, 2018
Primary Completion
August 3, 2020
Study Completion
September 13, 2021
Last Updated
August 2, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share